Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Joyce Majure who wrote (970)	6/10/1998 3:06:00 AM
From: Joyce Majure	Respond to of 1501

Maedel's has an interview in his May 31, 1998, issue. Basically, they spoke with Mr. McBeath, the new CEO at Inflazyme. He has had a strong track record in bringing new drugs to market for ICI Pharma (now Zeneca, maker of Tamoxifen of breast cancer fame, among others). He also has had experience with other biotechs, attracting grant money as well as investors and bringing at least one drug into Phase III clinical trials. McBeath appears to have excellent skills at developing and implementing strategic plans with these companies. Mr. McBeath was attracted to Inflazyme by the quality of its scientists, and its relationship with Goldman Sachs and Rothschild's. Maedel believes implementation will still take a while, and therefore still rates IZP a "hold." To quote Maedel, McBeath "comes across as very professional but cautious; he wants to undersell and overdeliver." We are waiting to see what he can do!!